Veru

Historical price data

Veru Inc. is a NASDAQ-lated biopharmaceutical company (VERU) with a focused mission to develop novel oral therapeutics for cardiometabolic and inflammatory diseases. Its core strategy leverages two late-stage assets: enobosarm, a SARM designed to combat muscle loss associated with GLP-1 weight loss drugs, and sabizabulin, an oral microtubule disruptor being repurposed as a broad anti-inflammatory for atherosclerosis. The company has reported positive Phase 2b topline results for enobosarm and is advancing both programs into further clinical trials, positioning itself at the intersection of two of healthcare's largest markets.

Development of proprietary small molecules with specific mechanisms: Selective Androgen Receptor Modulators (SARMs) for muscle preservation and oral microtubule disruptors for broad anti-inflammatory effects.

Enobosarm faces limited direct competition but must prove superiority over standard exercise/diet advice and safety over traditional anabolic agents. Sabizabulin enters a more crowded cardiovascular inflammation space against established generics (colchicine) and novel mechanisms, requiring a differentiated efficacy/safety profile.